Autonomix Medical, Inc. (NASDAQ:AMIX) Sees Significant Drop in Short Interest

Autonomix Medical, Inc. (NASDAQ:AMIX) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 658,692 shares, a drop of 57.3% from the December 31st total of 1,543,188 shares. Currently, 10.2% of the shares of the stock are short sold. Based on an average daily volume of 5,009,024 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 5,009,024 shares, the short-interest ratio is currently 0.1 days. Currently, 10.2% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Autonomix Medical in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Autonomix Medical presently has an average rating of “Hold” and an average price target of $5.00.

Autonomix Medical Stock Performance

Shares of NASDAQ AMIX opened at $0.40 on Friday. Autonomix Medical has a 52-week low of $0.38 and a 52-week high of $3.10. The stock has a market cap of $2.76 million, a P/E ratio of -0.09 and a beta of -2.59. The firm has a 50 day moving average price of $0.65 and a two-hundred day moving average price of $0.97.

Autonomix Medical (NASDAQ:AMIX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($1.38) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.38). Analysts predict that Autonomix Medical will post -10 earnings per share for the current fiscal year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.